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Background:CXCL13 is preferentially secreted by Follicular Helper T cells (TFH) to attract
B cells to germinal centers. Plasma levels of CXCL13 have been reported to be elevated
during chronic HIV-infection, however there is limited data on such elevation during early
phases of infection and on the effect of ART. Moreover, the contribution of CXCL13
to disease progression and systemic immune activation have been partially defined.
Herein, we assessed the relationship between plasma levels of CXCL13 and systemic
immune activation.
Methods: Study samples were collected in 114 people living with HIV (PLWH) who were
in early (EHI) or chronic (CHI) HIV infection and 35 elite controllers (EC) compared to 17
uninfected controls (UC). A subgroup of 11 EHI who initiated ART and 14 who did not
were followed prospectively. Plasma levels of CXCL13 were correlated with CD4T cell
count, CD4/CD8 ratio, plasma viral load (VL), markers of microbial translocation [LPS,
sCD14, and (1→3)-β-D-Glucan], markers of B cell activation (total IgG, IgM, IgA, and
IgG1-4), and inflammatory/activation markers like IL-6, IL-8, IL-1β, TNF-α, IDO-1 activity,
and frequency of CD38+HLA-DR+ T cells on CD4+ and CD8+ T cells.
Results: Plasma levels of CXCL13 were elevated in EHI (127.9 ± 64.9
pg/mL) and CHI (229.4 ± 28.5 pg/mL) compared to EC (71.3 ± 20.11
pg/mL), and UC (33.4 ± 14.9 pg/mL). Longitudinal analysis demonstrated that
CXCL13 remains significantly elevated after 14 months without ART (p < 0.001)
and was reduced without normalization after 24 months on ART (p = 0.002).
Correlations were observed with VL, CD4T cell count, CD4/CD8 ratio, LPS,
sCD14, (1→3)-β-D-Glucan, total IgG, TNF-α, Kynurenine/Tryptophan ratio, and
frequency of CD38+HLA-DR+ CD4 and CD8T cells. In addition, CMV+ PLWH
presented with higher levels of plasma CXCL13 than CMV- PLWH (p = 0.005).
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Conclusion: Plasma CXCL13 levels increased with HIV disease progression. Early
initiation of ART reduces plasma CXCL13 and B cell activation without normalization.
CXCL13 represents a novel marker of systemic immune activation during early and
chronic HIV infection and may be used to predict the development of non-AIDS events.
Keywords: CXCL13, humoral immune response, microbial translocation, inflammation, immune activation, CMV
INTRODUCTION
Despite the success of antiretroviral therapy (ART), people living
with HIV (PLWH) still suffer from chronic immune activation
and the development of non-AIDS events (1). Progressive CD4T
cell decline, elevated CD8T cell counts, early damage to the
intestinal mucosa, microbial translocation, CMV co-infection,
and persistence of HIV in cellular reservoirs all contribute to
systemic immune activation (2–6). Chronic immune activation
and inflammation among PLWH on ART have been linked
with increased risk for mortality and development of non-AIDS
events such as cardiovascular dysfunction, renal failure, hepatic
steatosis, neurocognitive degeneration, accelerated aging, and
cancer (7, 8). Therefore, therapeutic strategies are needed to
tackle residual immune activation to improve the quality of life
of PLWH.
Apart from the virus itself or its proteins, factors contributing
to immune activation among PLWH include elevated circulation
of microbial products leaking from the gut and CMV infection
(9, 10). It has been reported that epithelial gut damage,
leading to microbial translocation, precedes systemic immune
activation in a SIV-infected rhesus macaque model of the disease
(11). Circulation of gram-negative bacterial cell wall antigen,
lipopolysaccharide (LPS), and major component of fungal cell
walls, (1→3)-β-D-Glucan (βDG), have been reported to be
elevated in the plasma of PLWH (12–16). These markers of
microbial translocation have been previously associated with
activated CD4 and CD8T cells, indoleamine 2,3-dioxygenase 1
(IDO-1) activity, and plasma levels of inflammatory cytokines.
Thus, the optimal marker of systemic immune activation in
PLWH should account for the contribution of circulating
microbial products LPS and βDG.
Several cellular and soluble markers of immune
activation/inflammation have been identified (17). Frequencies
of HLA-DR and CD38 expressing CD4 and CD8T cells are
used to measure lymphoid cell activation (18). Inflammatory
myeloid cells including monocytes, macrophages, and dendritic
cells (DC) are reported to induce IDO-1 enzyme activity upon
antigen stimulation (19). IDO-1 converts essential amino acid
tryptophan into immune suppressive kynurenines. Frequency
of activated CD4 and CD8T cells as well as IDO-1 activity of
myeloid cells have been associated with the degree of epithelial
gut damage, microbial translocation, and size of HIV reservoir
(1, 20–22). Plasma level markers of inflammation/immune
activation include marker of monocyte activation soluble CD14
(sCD14) as well as inflammatory cytokines such as IL-6, IL-1β,
IL-8, and TNF-α which are secreted by activated immune cells
(23–25). While there are several validated markers of immune
activation/inflammation in PLWH, there is currently no single
marker that can account for both lymphoid and myeloid cell
activation during early and chronic stages of HIV infection.
B cells play a crucial role in mounting an antiviral humoral
immune response. Upon maturation in germinal centers (GCs),
they are mainly localized in secondary lymphoid tissues where
they present antigens, secrete cytokines, and produce antigen-
specific antibodies (26). PLWH have been reported to have
humoral immune dysfunction that is regulated by GCs, which
have been linked to HIV-associated immune activation (27–29).
Both structural and functional impairment of lymph node GCs
lead to B cell dysfunction. Subsequent B cell activation results in
hypergammaglobulinemia, impaired antibody response, and loss
of B cell memory (27). B cell activation and trafficking to lymph
node GCs is controlled by secretion of chemokine CXCL13 [(C-
X-C motif) ligand 13] that is recognized by leukocytes, which
express CXCR5. As such, CXCL13 is considered as a marker
of GC activity as it is secreted by follicular DC and helper T
(TFH) cells. Furthermore, myeloid cells such as macrophages
have also been reported to secrete CXCL13 upon activation
(30). It has been previously reported that PLWH have elevated
plasma levels of CXCL13 during chronic infection (31). However,
plasma levels of CXCL13 during early infection, the effect of
ART on CXCL13 secretion, and the contribution of CXCL13
to HIV disease progression and systemic immune activation
are poorly understood. Herein, we assessed the validity of
plasma levels of CXCL13 as a biomarker of systemic immune
activation in a well-defined cohort of early and chronic, untreated
and treated PLWH.
METHODS
Study Design and Population
114 adult PLWH were cross-sectionally grouped into those in
early HIV-infection (EHI) (n = 37), defined as being within
6 months of the estimated date of infection, and those with
chronic HIV-infection (CHI) who were either untreated (n =
13) or ART treated (n = 64). EHI participants were enrolled
from the Montreal Primary HIV Infection Study (32); while CHI
participants were enrolled from the Chronic Viral Illness Service
at the McGill University Health Centre and Canadian HIV and
Aging Cohort Study (33). In addition, 35 elite controllers (EC)s,
defined as PLWHwho control plasma viral loads below 50 copies
per mL and maintain CD4 T-cell counts above 500 cells per mm3
in the absence of ART were included from the Canadian Cohort
of HIV-infected Slow Progressors (34). Within the EHI group,
24 participants were prospectively followed-up for about 2 years.
During the follow-up, 10 EHI participants were on ART for at
Frontiers in Immunology | www.frontiersin.org 2 February 2019 | Volume 10 | Article 289
Mehraj et al. CXCL13 as a Biomarker of HIV-Associated Immune Activation
least 1 year while the remaining participants were ART naïve
during the time of longitudinal assessment. A group of 17 HIV-
uninfected controls (UC) were assessed for comparison with EHI
and CHI groups.
Laboratory Measurements
Participants were diagnosedwithHIV bymeasuring plasmaHIV-
1 p24 antigen/antibody and were further confirmed by Western
blot as previously reported (32, 35). HIV viral load (VL) in plasma
was quantified by the Abbott RealTime HIV-1 assay (Abbott
Laboratories, Abbott Park, Illinois, U.S.A). Assessment of CD4
and CD8T cell counts was done by 4-color flow cytometry.
For further research measurements blood samples of study
participants were collected to isolate plasma and peripheral blood
mononuclear cells (PBMC) samples and stored at −80◦C and in
liquid nitrogen, respectively. All participants were fasting at the
time of blood collection.
Quantification of Plasma Levels of CXCL13
Plasma CXCL13 levels were measured in duplicate by using
the Human CXCL13/BLC/BCA-1 Quantikine ELISA Kit (R&D
Systems, Minneapolis, MN), a 4.5-h solid phase enzyme linked
immunosorbent assay (ELISA).
Quantification of Markers of B-Cell Activity
(Total IgG, IgM, IgA, IgG1-4, BAFF, sCD40L)
Total IgG, IgM, and IgA were measured using the Olympus
AU5800 (Beckman Coulter). Further subclasses of IgG (IgG1,
IgG2, IgG3, and IgG4) were measured by using ELISA kits
(eBiosciences, Saint Laurent, QC, Canada) as per manufacturer’s
instructions. B cell activating factor (BAFF) and soluble CD40L
(sCD40L) were measured in duplicate using an ELISA (R&D
Systems, Minneapolis, MN, USA).
Quantification of Markers of Epithelial Gut
Damage and Microbial Translocation
Intestinal-fatty acid binding protein (I-FABP) was measured
using an ELISA kit (Hycult Biotech, Uden, Netherlands).
Soluble suppressor of tumorigenicity 2 (sST2) was measured
by ELISA as described before (21). LPS was measured using a
human lipopolysaccharide ELISA kit (Cusabio, Wuhan, China).
sCD14 was measured by immunoassay (Quantikine, R&D
Systems, Minneapolis, MN, USA). (1→3)-β-D-Glucan (βDG)
was measured by the Fungitell R© Limulus Amebocyte Lysate
assay (Associates of Cape Cod, Inc., East Falmouth, MA,
USA). All the analytes were measured in duplicate as per
manufacturer’s instructions.
Multiplex Quantification of Soluble
Inflammatory Markers
Plasma levels of IL-1β, Tumor Necrosis Factor α (TNF-α), IL-
6, and IL-8 were measured in duplicate using the Meso Scale
Discovery (MSD) U-Plex Pro-Inflammatory Combo 4 kit (MSD,
Rockville, Maryland, USA).
Measurement of Kynurenine and
Tryptophan Plasma Levels
Kynurenine and Tryptophan were measured using an automated
on-line solid-phase extraction-liquid chromatographic-tandem
mass spectrometric method (36, 37). Ratio of kynurenine
to tryptophan was calculated as a measure of IDO-1
enzyme activity.
Flow Cytometry Analyses
Frozen PBMC samples were rapidly thawed and stained
for 20min at 4◦C using fluorochrome conjugated antibody
panels from BD Biosciences (Mississauga, ON, Canada) or
BioLegend (San Diego, CA, USA) using anti-CD56-FITC, anti-
CD11c BV711, anti-CD3 PE-Dazzle594, anti-CD4 BUV395,
anti-CD8 BUV737, anti-CD38 BV605, anti-HLADR APC-Cy7.
Cells were then washed and fixed in 2% paraformaldehyde
before acquisition. CD38 and HLA-DR expression were analyzed
on CD4 and CD8T cells. Dead cells were excluded as
Live/dead positive (ThermoFisher, Saint Laurent QC, Canada).
Fluorescence minus one color controls were used to discriminate
auto-fluorescence from positive signals. BD Fortessa X20 flow
cytometer was used for FACS and the data was analyzed using
FlowJo 10.0.7 (FLOWJO, LLC, Ashland, OR, USA).
In vitro Stimulations
One million PBMC from uninfected donors were stimulated for
18 h in 1mL complete medium [RPMI (Wisent) + 10% FBS
(Wisent) + 1% Penicillin/Streptomycin (ThermoFisher)] with
1µg/ml of LPS (Sigma), βDG (Sigma) or both. Supernatants were
collected and CXCL13 was measured as previously described.
Statistical Analyses
Descriptive and inferential analyses were conducted using SPSS
24.0 (Chicago, IL, USA) and GraphPad Prism 6.0 (La Jolla,
CA, USA). Data were summarized using means and standard
deviations calculated for the variables with normal distribution
and using median with interquartile range (IQR) calculated
for variables with a non-normal distribution. Percentages
were calculated for categorical variables. Subsequently, both
parametric and non-parametric tests including student t, chi-
square, Mann-Whitney U, χ2, and ANOVA with LSD test
were used for comparisons. Paired t-test was used for before-
after comparisons. Pearson correlation test was conducted to
assess association between two quantitative variables. Statistical
significance was determined at p < 0.05. Multivariate linear
regression analysis was conducted to determine the independent
association of CXCL13 with HIV-infection adjusting for the
confounding factors such as age, sex, CD4T cell count and
inflammatory markers.
RESULTS
Clinical Characteristics of Study
Participants
Eighty one percent of the participating PLWHwere male and the
median (IQR) age was 47 (37–51). CD4 T-cell count was lower in
untreated EHI and CHI vs. controls, which increased amongst
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Median (IQR) 480 (368–650) 81 (14–319) 605 (412–700) 650 (552–823) 866 (566–1,022)
CD8T cells/µL
Median (IQR) 810 (630–1,030) 1,030 (267–1,232) 746 (554–1,001) 690 (409–968) 408 (281–689)
CD4/CD8
Median (IQR) 0.6 (0.4–0.9) 0.1 (0.1–0.4) 0.8 (0.5–1.1) 1.1 (0.8–1.4) 1.7 (1.2–3.0)
VL (log10 copies/mL)
Median (IQR) 4.4 (3.7–5.0) 5.1 (4.6–5.3) <1.7 <1.7 NA
EHI, early HIV infection; ART, antiretroviral therapy; CHI, chronic HIV infection; EC, elite controllers; UC, uninfected controls; NA, not applicable.
FIGURE 1 | Plasma levels of CXCL13 over the course of HIV-infection. (A) Circulating CXCL13 during early and chronic infection compared to elite controllers and
uninfected controls. EHI ART– (n = 37), CHI ART– (n = 13), EC (n = 35), UC (n = 17). (B) Comparison of plasma levels of CXCL13 in CMV+ and CMV– HIV-infected
progressors with similar CD4T cell count. EHI, early HIV infection; CHI, chronic HIV infection; EC, elite controllers; UC, uninfected controls; ART, antiretroviral therapy.
**p < 0.01; ****p < 0.0001.
those receiving antiretroviral therapy (ART). In contrast, CD8
T-cell count among untreated PLWH was higher than those
receiving ART. Untreated EHI and CHI groups had a median
log10 plasma viral loads of 4.4 (3.7–5.0) and 5.1 (4.6–5.3) copies
per mL, respectively. All the participants on ART and all ECs had
plasma viral loads <50 copies/mL (Table 1).
Elevation of Plasma CXCL13 Levels During
Early and Chronic HIV Infection and Impact
of Antiretroviral Therapy
Plasma levels of CXCL13 were significantly elevated in ART-
naive EHI (137.3 ± 67.4 pg/mL) and ART-naive CHI (385.91
± 76.8 pg/mL) compared to EC (71.3119.0 pg/mL) and UC
(33.414.9 pg/mL) (Figure 1A). EC had lower levels of plasma
CXCL13 than EHI and CHI but still had nearly two-fold
more CXCL13 than UC. However, this difference was not
statistically significant. This is likely because EC are known to
have a comparatively preserved immune system compared to
progressors (38). We observed PLWH with CMV co-infection
to have higher plasma levels of CXCL13 than PLWH without
CMV co-infection (p = 0.005) (Figure 1B). Of note, CMV
co-infection has been reported to be linked to HIV-associated
immune activation (39). In cross-sectional analysis, both EHI and
CHI groups on ART compared to their untreated counterparts
showed a significant decrease in their CXCL13 levels without
normalization. Longitudinal analysis of the EHI participants that
remained without ART for a median of 24 months demonstrated
that their plasma CXCL13 levels increased from 133.2 ± 17.3
to 260.5 ± 30.4 pg/mL (p < 0.001). On the other hand, EHI
participants who received ART for a median of 24 months
showed a decrease in their CXCL13 levels without normalization
(81.6± 10.3 pg/mL, p= 0.002) (Figure 2). It is important to note
that while there is an overall trend of reduced plasma levels of
CXCL13 after 24 months of ART, such reduction is pronounced
in two participants.
These results suggest that plasma levels of CXCL13
progressively increases with HIV disease progression and is
Frontiers in Immunology | www.frontiersin.org 4 February 2019 | Volume 10 | Article 289
Mehraj et al. CXCL13 as a Biomarker of HIV-Associated Immune Activation
FIGURE 2 | Effect of ART on plasma levels of CXCL13. (A) Cross-sectional analysis on the effect of ART on plasma levels of CXCL13 (EHI ART+ n = 11; CHI ART+ n
= 64; UC n = 17). (B) Longitudinal analysis on the change of plasma levels of CXCL13 over 24 months in PLWH without ART (n = 14). (C) Longitudinal analysis on
the change of plasma levels of CXCL13 in PLWH after 24 months on ART (n = 10). EHI, early HIV infection; CHI, chronic HIV infection; UC, uninfected controls; ART,
antiretroviral therapy. **p < 0.01.
FIGURE 3 | Association of plasma levels of CXCL13 with markers of HIV disease progression. (A) Plasma levels of CXCL13 are correlated with CD4T cell count in
HIV-infected progressors (n = 144). (B) Plasma levels of CXCL13 are correlated with CD4/CD8T cell ratio in HIV-infected progressors (n = 144). (C) Plasma levels of
CXCL13 are correlated with plasma viral load in untreated PLWH (n = 72).
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FIGURE 4 | Plasma levels of CXCL13 are associated with immunoglobulin
production. (A) Plasma levels of CXCL13 are correlated with plasma levels of
non-specific IgG in a subset of EHI and CHI PLWH, including participants on
and off ART (n = 49). (B) Plasma levels of CXCL13 are correlated with plasma
levels of non-specific IgG1 in a subset of EHI and CHI PLWH, including
participants on and off ART (n = 51).
decreased without normalization upon initiation of ART. This
is in line with previous findings that ART results in a decrease
without normalization of systemic immune activation (40).
Multivariate analysis confirmed that elevated CXCL13 levels
among PLWH were independent of the effect of age, sex, HIV
viral load, CD4T cell count, and inflammatory markers.
Correlation of Plasma CXCL13 Levels With
CD4 and CD8 T-Cell Counts, CD4/CD8 T
Cell Ratio and Plasma Viral Load
Among PLWH, CXCL13 levels correlated negatively with both
CD4 T-cell count (r = −0.359; p < 0.001) and CD4/CD8 T cell
ratio (r =−0.303; p < 0.001) but not with CD8 T-cell count (r =
0.107; p= 0.232, data not shown). Elevated CXCL13 levels among
untreated participants (both EHI and CHI) positively correlated
with viral load (r = 0.382; p < 0.001) (Figures 3A–C) (41).
Correlation of Plasma CXCL13 Levels With
B-Cell Activation Markers
CXCL13 levels correlated with total IgG (r = 0.649; p < 0.001),
and IgG1 (r = 0.338; p = 0.02) in circulation (Figures 4A,B),
while no correlation was observed with IgG2, IgG3, nor
IgG4 (data not shown). Similarly, despite a positive trend,
the correlation of plasma CXCL13 was not significant with
plasma BAFF and sCD40L levels, two other indicators of B-cell
activity (data not shown). These results highlight the distinctive
contribution of CXCL13 in B-cell activation and humoral
immune response.
Correlation of Plasma CXCL13 Levels With
Soluble Markers of Gut Damage and/or
Microbial Translocation
Plasma CXCL13 did not correlate with marker of epithelial gut
damage, I-FABP (data not shown). We also assessed sST2 as
an emerging marker of gut damage (21). CXCL13 levels did
not show any correlation with sST2 (data not shown). However,
plasma levels of gram-negative bacterial cell wall endotoxin LPS
and monocyte activation marker sCD14 positively correlated
with systemic CXCL13 levels (r = 0.332; p < 0.001 and r =
0.322; p = 0.005, respectively) (Figures 5A,B). Both LPS and
sCD14 are considered as markers of bacterial translocation. In
addition, we also measured fungal translocation using a major
fungal cell wall polysaccharide antigen, βDG (42). Plasma levels
of βDG correlated significantly with plasma CXCL13 (r = 0.257;
p= 0.03) (Figure 5C). Of note, βDGhas been used as a diagnostic
marker for invasive fungal infections and its role is emerging
in HIV-associated fungal translocation as we and others have
previously reported (13, 15, 43). In vitro, both LPS and βDG
induced CXCL13 secretion by PBMC from uninfected donors.
Combination of both LPS and βDG did not show an additive
effect on CXCL13 secretion compared to LPS or βDG alone (data
not shown).
Correlation of Plasma CXCL13 Levels With
Soluble Markers of Inflammation and/or
Immune Activation
Plasma TNF-α levels were observed to have a significant
positive correlation with circulating CXCL13 levels (r = 0.316;
p < 0.001, Figure 6A), while no correlation of CXCL13 was
observed with other inflammatory markers IL-1β, IL-6, and IL-
8 (data not shown). We also quantified plasma Tryptophan
and Kynurenine levels to measure IDO-1 enzyme activity as a
marker of myeloid cell inflammation and/or immune activation.
Plasma CXCL13 levels had a significant positive correlation
with plasma kynurenine (r = 0.569; p < 0.001, Figure 6B). We
computed ratio of kynurenine to tryptophan as a measure of
IDO-1 enzyme activity. This ratio further significantly correlated
(r = 0.653; p < 0.001, Figure 6C) with plasma CXCL13 levels.
Taken together, these results portray the involvement of CXCL13
in HIV-associated myeloid cell activation and inflammation.
Correlation of Plasma CXCL13 Levels With
Lymphocyte Activation Markers
We analyzed PBMC by FACS for whom samples were available.
Frequency of CD38+HLA-DR+ CD4T cells (r = 0.561; p =
0.04, Figure 6D) and frequency of CD38+HLA-DR+ CD8T cells
(r = 0.527; p = 0.02, Figure 6E) correlated with plasma levels
of CXCL13. These findings highlight CXCL13 as a plasma level
biomarker of lymphoid cell activation.
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FIGURE 5 | Plasma levels of CXCL13 are associated with markers of microbial translocation. (A) Plasma levels of CXCL13 are correlated with plasma levels of LPS
(n = 144). (B) Plasma levels of CXCL13 are correlated with plasma levels of soluble CD14 (sCD14), in a subset of EHI and CHI PLWH, including those on and off ART
(n = 74). (C) Plasma levels of CXCL13 are correlated with plasma levels of (1→3)-β-D-Glucan (βDG), in a subset of EHI and CHI PLWH, including those on and off
ART (n = 68).
DISCUSSION
We report significant elevation of plasma CXCL13 levels
during early and chronic HIV infection that reduced without
normalization in PLWH receiving antiretroviral therapy. To our
knowledge, this is the first observation reporting a correlation
of CXCL13 levels with markers of microbial translocation,
inflammatory cytokines, IDO-1 enzyme activity and markers of
myeloid and lymphoid cell activation in PLWH. In addition, we
also showed a significant correlation of plasma CXCL13 levels
with markers of B cell activation in the context of HIV infection.
Interestingly, plasma levels of CXCL13 were also associated with
CMV co-infection which was reported to be a contributor to
HIV-associated systemic inflammation (39). Immune activation
is considered as a major factor contributing to the size of HIV
reservoirs and development of non-AIDS events despite long-
term ART (1, 4, 7). Therefore, therapeutic strategies targeting
immune activation remains a priority for curing HIV infection.
Our results are in line with the first report of elevated CXCL13
levels in PLWH. Widney et al. observed a positive correlation
of plasma CXCL13 with inflammatory markers and with CD4
T cell count in chronically infected patients (31). In contrast,
we observed a negative correlation of CXCL13 with CD4 T cell
counts and CD4/CD8 T cell ratio. Progressive decline in the
CD4 T cell numbers and CD4/CD8 T cell ratio is a hallmark
of HIV-infection (44, 45). Therefore, their negative correlation
with CXCL13 levels explains a role of the later in HIV-disease
progression via immune activation. Furthermore, in untreated
participants, we observed a correlation of plasma CXCL13
with viral load. In untreated participants, the associations of
plasma CXCL13 with CD4T cell count, CD4/CD8 ratio, LPS,
sCD14, βDG, and IDO-1 metabolism were independent of HIV
viral load.
Moreover, Widney et al. did not observe an association of
CXCL13 levels and immunoglobulins. On the other hand, we
found a correlation of CXCL13 with IgG and more specifically
with its predominant subclass IgG1. This observation shows
concordance of plasma CXCL13 levels with B cell activation,
which is mediated via CXCR5 expression (46).
Chronic immune activation and inflammation are understood
to be the driving factors of HIV disease progression and a
significant underlying cause of non-AIDS events in PLWH on
long-term ART. As such, it is of clinical interest to validate
a biomarker that can monitor myeloid and lymphoid cell
activation/inflammation in early and chronic stages of infection
in both progressors and non-progressors. In these lines, TFH
cells are reported to secrete CXCL13 (47). Cohen et al. have
shown that HIV-1 ssRNA induces the production of CXCL13
by DC (48). Furthermore, Carlsen et al. showed that LPS
stimulates macrophages to produce CXCL13 in vitro (30). We
show plasma levels of CXCL13, measured by ELISA, to be a
valid marker of HIV disease progression (CD4T cell count and
plasma viral load), microbial translocation (circulation of LPS
and βDG), myeloid cell activation (IDO-1 activity and plasma
sCD14 levels), lymphoid cell activation (frequency of CD38+
HLA-DR+ CD4 and CD8T cells), and general inflammation
(plasma levels of TNF-α). Thus, we propose plasma levels of
CXCL13 as a marker of systemic myeloid and lymphoid cell
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FIGURE 6 | Plasma levels of CXCL13 are associated with markers of myeloid and lymphoid activation. (A) Plasma levels of CXCL13 are correlated with plasma levels
of TNF-α (n = 139). (B) Plasma levels of CXCL13 are correlated with plasma levels of Kynurenine, in a subset of PLWH in early and chronic stages of infection,
including those on and off ART (n = 84). (C) Plasma levels of CXCL13 are correlated with IDO-1 metabolism (Kynurenine/Tryptophan), in a subset of EHI and CHI
participants including those on and off ART (n = 84). (D) Plasma levels of CXCL13 are correlated with frequency of HLA-DR+CD38+ CD4T cells, in a random subset
of PLWH from early and chronic HIV-infection (n = 13). (E) Plasma levels of CXCL13 are correlated with frequency of HLA-DR+CD38+ CD8T cells, in a random
subset of PLWH from early and chronic HIV-infection (n = 18).
activation and inflammation in PLWH. Future studies should
investigate the contribution of CXCL13 to the development of
non-AIDS events and assess if plasma levels of CXCL13 can
be used as a prognostic marker for the development of certain
non-AIDS events including lymphoma.
TFH cells in GCs and follicular DC in B cell follicles are major
producers of CXCL13 owing to their expression of CXCL13
receptor CXCR5 (41, 46, 49). CXCL13 overexpression has been
associated with immune activation in chronic conditions such
as infection with HIV and systemic sclerosis (31, 50). Havenar-
Daughton et al. studied a large longitudinal cohort of PLWH
and reported a significant elevation of plasma CXCL13 with the
generation of broad neutralizing antibodies (bnAbs) against HIV
(41). They further correlated plasma CXCL13 levels with the
magnitude of Ab responses and the frequency of TFH-like cells
expressing ICOS in the blood of individuals’ post-vaccination.
Similarly, we observed an association of plasma CXCL13 with
Abs such as total IgG and its subtype IgG1 in PLWH. Taken
together, such findings display CXCL13 not only as another
marker but also as an indicator of GC activity, which is
influenced by non-specific and specific stimuli, inflammation,
and vaccine response.
Our study has certain limitations that need to be considered
while interpreting these findings. Causality cannot be determined
as an inherent bias in observational studies like ours despite
being conducted on well-defined clinical cohorts. Therefore, this
study could not rule out the possibility that the dysfunction
caused by chronic immune activation contributes to an
increase in plasma CXCL13. Furthermore, limited sample
availability did not allow us to assess whether plasma levels
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of CXCL13 is a marker of immune activation in known HIV
reservoirs such as the gut (51). Our multivariate model did
not account for potential confounding factors such as risk
behaviors, economic status, smoking, alcohol, and drug abuse.
Future studies should consider these limitations to further
highlight the role of CXCL13 as a biomarker of immune
activation among PLWH. Nevertheless, our study represents
a novel and comprehensive assessment of plasma CXCL3 in
the context of immune activation among PLWH with early
HIV infection, before initiation of ART and while being
on ART.
CONCLUSION
Globally, our results suggest that elevated plasma levels of
CXCL13 in PLWH are partially restored on ART and remains
associated with markers of microbial translocation and systemic
immune activation. Elevated CXCL13 levels can be used
to monitor HIV disease progression and inflammation.
Furthermore, it has potential to be used to predict the
development of non-AIDS events and residual immune
activation after long-term ART.
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